The Digest.

The Peter Attia Drive · Podcast summary

#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

Dr. Brian Grosberg, a leading headache specialist, discusses the symptoms, causes, prevention, and treatment of migraine, cluster headache, and tension headache.

#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D. Listen on the show ↗

Key takeaways

Chapters

The digest

Dr. Brian Grosberg, a renowned headache specialist and professor of neurology, joins Peter Attia to demystify the complex world of headaches. This episode delves into the classification, symptoms, causes, prevention, and treatment strategies for migraine, cluster headache, and tension headache, offering invaluable insights for both patients and clinicians.

The Under-recognized Burden of Headaches

Dr. Grosberg highlights that headaches are one of the most common neurological symptoms, with nearly everyone experiencing one at some point in their lives. Despite this widespread prevalence, headache education in medical school and neurology residencies is surprisingly limited, often amounting to just a few hours of lectures. This educational gap contributes to the significant misunderstanding and underdiagnosis of headache disorders, particularly migraine. Peter shares a personal anecdote about a patient whose debilitating migraines led him to Dr. Grosberg, emphasizing the profound impact these conditions have on individuals' lives and the rarity of specialists like Dr. Grosberg.

Keep reading in The Digest

The full 2-minute article, 2 more sections, and every new episode from The Peter Attia Drive and the creators you follow.

  1. Classifying Headaches: Primary vs. Secondary
  2. The Big Three: Tension, Migraine, and Cluster Headaches
Read the full digest — free

More from The Peter Attia Drive

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

Dr. Lloyd Klickstein, a physician-scientist and drug developer, reveals the intricate science, economics, and regulatory challenges behind modern drug development, using the muscle and obesity drug Bimagrumab as a case study.

September 28, 2026

#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Dr. Michael Davidson, a cardiologist and lipidologist, discusses the critical importance of early and aggressive LDL-C lowering for preventing cardiovascular disease, the nuanced role of HDL-C, and the exciting potential of new therapies like obicetrapib and clotho for both cardiovascular and Alzheimer's disease prevention.

September 14, 2026

Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

Peter Attia and his co-host discuss blood pressure, its importance for longevity, how to accurately measure it at home, and the latest evidence on optimal blood pressure targets and interventions.

September 7, 2026

#405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease

Dr. Peter Attia discusses the liver's critical role in metabolic health, explaining how to assess risk, catch dysfunction early, and prevent or reverse liver disease.

August 24, 2026

#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

Dr. Linus Abrams, a psychiatrist with 35 years of clinical experience, discusses the limitations of traditional psychiatry and how an integrative approach, focusing on hormones, metabolism, and inflammation, offers a broader framework for understanding and treating mental health conditions.

August 17, 2026

#403 ‒ Peptides: separating scientific promise from marketing hype

Peter Attia and Nick Stenson discuss the complex world of peptides, distinguishing between scientifically supported applications and marketing hype, and providing a framework for evaluating their efficacy and safety.

August 10, 2026

All The Peter Attia Drive summaries →